Iron Horse Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Iron Horse Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$1.57K	Hold	3	–	–	﹤0.01%	491
2025 Q1	$1.9K	Hold	3	–	–	﹤0.01%	467
2024 Q4	$2.14K	Hold	3	–	–	﹤0.01%	387
2024 Q3	$3.15K	Hold	3	–	–	﹤0.01%	339
2024 Q2	$3.15K	Hold	3	–	–	﹤0.01%	313
2024 Q1	$2.89K	Hold	3	–	–	﹤0.01%	307
2023 Q4	$2.63K	Hold	3	–	–	﹤0.01%	333
2023 Q3	$2.47K	Buy	+3	New	+$2.36K	﹤0.01%	332

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Iron Horse Wealth Management's REGN Position: Q2 2025 in Review

Iron Horse Wealth Management held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2025 at 3 shares worth $1.57K. The position accounts for ﹤0.01% of the portfolio, ranked #491.

Iron Horse Wealth Management first reported a position in REGN in Q3 2023 and has held it in 8 quarters since. The position peaked at $3.15K in Q3 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Iron Horse Wealth Management held 3 shares of Regeneron Pharmaceuticals worth $1.57K as of Q2 2025.
Iron Horse Wealth Management left its Regeneron Pharmaceuticals share count unchanged in Q2 2025.
Regeneron Pharmaceuticals made up ﹤0.01% of Iron Horse Wealth Management's portfolio in Q2 2025, its #491 holding.
Iron Horse Wealth Management first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 8 quarters since.
Iron Horse Wealth Management's Regeneron Pharmaceuticals position peaked at $3.15K in Q3 2024.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Iron Horse Wealth Management's 13F filing for Q2 2025, filed 22 Jul 2025.